Pre-made Vudalimab biosimilar ( Bispecific Mixed mAb and scFv, anti-CTLA4;PDCD1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-631
Anti-CTLA4;PDCD1 therapeutic antibody (Pre-made Vudalimab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor's proprietary XmAb? technology) that increases binding affinity to the receptor FcRn.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CTLA4;PDCD1 therapeutic antibody (Pre-made Vudalimab biosimilar,Bispecific Mixed mAb and scFv)|
|Format||Bispecific Mixed mAb and scFv|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None|
|Conditions Active||Solid tumours|